ALA Arovella Therapeutics Ltd
- 0.117
- +0.002+1.74%
Arovella Therapeutics Ltd News
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise
Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors to raise about AU$12.5 million via a placement of 125 million new fully paid ordinary share
While Shareholders of Arovella Therapeutics (ASX:ALA) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%
Arovella Therapeutics (ASX:ALA) said its collaboration with Imugene (ASX:IMU) to combine ALA‐101 and onCARlytics has ended, effective immediately, according to a Wednesday filing with the Australian S
Arovella Boosts Solid Tumor Pipeline With Novel CAR-iNKT Cell Armouring Tech License
Arovella Therapeutics (ASX:ALA) secured an exclusive license from the University of North Carolina Lineberger Comprehensive Cancer Center to integrate cytokine technology into its CAR-iNKT cell platfo
Arovella Therapeutics Well-placed to Advance INKT Cell Therapy Cancer Treatment Towards First-in-human Clinical Trials
Arovella Therapeutics Ltd (ASX:ALA) capped off the December quarter in a “solid financial position” with pro-forma cash and cash equivalents of $4.76 million to continue advancing its iNKT cell therapy platform for cancer treatment towards first-in-human clinical trials.
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%
Biotechnology company Arovella Therapeutics (ASX:ALA) said Tuesday that the manufacturing of the good manufacturing practice (GMP)‐grade lentiviral vector for its lead product, ALA‐101, has been compl
Arovella Therapeutics Takes Key Manufacturing Step on ALA-101's Path to Clinic
Arovella Therapeutics Ltd (ASX:ALA) has completed a key manufacturing step to progress lead product ALA-101 to clinic with its Good Manufacturing Practice (GMP)-grade lentiviral vector for ALA-101 successfully manufactured and quality release testing passed.
Arovella Therapeutics Appoints CFO
Arovella Therapeutics (ASX:ALA) appointed Tim Luscombe as chief financial officer and company secretary, effective Friday. Luscombe replaced Phillip Hains, who has been CFO and company secretary since
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023
Arovella Therapeutics (ASX:ALA) secured a AU$1.9 million rebate for the fiscal year ended June 30 as part of the Australian government's research and development tax incentive scheme. Proceeds will be
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady
Australian shares were flat with a positive bias on Thursday as minutes of the recent US Federal Reserve meeting raised market hopes that the central bank will keep rates steady. The S&P/ASX 200 Index
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%
Arovella Therapeutics (ASX:ALA) secured an exclusive global license to develop an off-the-shelf cancer tumor-targeting therapy using the monoclonal antibody SPX-101 owned by biopharmaceutical firm Spa
Is Arovella Therapeutics (ASX:ALA) In A Good Position To Invest In Growth?
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan
Arovella Therapeutics (ASX:ALA) raised AU$2.2 million from an oversubscribed share purchase plan to advance lead product ALA-101 towards a phase one clinical trial.
Arovella Therapeutics (ASX:ALA) "Thrilled" With $2.2m Oversubscribed SPP
Arovella Therapeutics Extends Closing Date of Share Purchase Plan
Arovella Therapeutics (ASX:ALA) extended the closing date of its AU$1 million share purchase plan to Thursday, July 6 from the previous closing date of June 29, the biotechnology firm said on Thursday.
Multiple Insiders Bought Arovella Therapeutics Limited (ASX:ALA) Stock Earlier This Year, a Positive Sign for Shareholders
Analysis
Price Target
No Data
